Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.
2.

[Identification and in vitro antifungal susceptibility of vaginal Candida spp. isolates to fluconazole, clotrimazole and nystatin].

Diaz MC, Camponovo R, Araya I, Cerda A, Santander MP, Carrillo-Muñoz AJ.

Rev Esp Quimioter. 2016 Jun;29(3):151-4. Epub 2016 May 11. Spanish.

3.

Candida and candidaemia. Susceptibility and epidemiology.

Arendrup MC.

Dan Med J. 2013 Nov;60(11):B4698. Review.

PMID:
24192246
4.

Species distribution and susceptibility profile to fluconazole, voriconazole and MXP-4509 of 551 clinical yeast isolates from a Romanian multi-centre study.

Minea B, Nastasa V, Moraru RF, Kolecka A, Flonta MM, Marincu I, Man A, Toma F, Lupse M, Doroftei B, Marangoci N, Pinteala M, Boekhout T, Mares M.

Eur J Clin Microbiol Infect Dis. 2015 Feb;34(2):367-83. doi: 10.1007/s10096-014-2240-6. Epub 2014 Sep 16.

PMID:
25224578
5.
6.

Colonization of the oral cavity by yeasts in patients with chronic renal failure undergoing hemodialysis.

Godoy JS, de Souza Bonfim-Mendonça P, Nakamura SS, Yamada SS, Shinobu-Mesquita C, Pieralisi N, Fiorini A, Svidzinski TI.

J Oral Pathol Med. 2013 Mar;42(3):229-34. doi: 10.1111/jop.12003. Epub 2012 Sep 17.

PMID:
22978344
7.

Results from the ARTEMIS DISK Global Antifungal Surveillance study, 1997 to 2005: an 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing.

Pfaller MA, Diekema DJ, Gibbs DL, Newell VA, Meis JF, Gould IM, Fu W, Colombo AL, Rodriguez-Noriega E; Global Antifungal Surveillance Study.

J Clin Microbiol. 2007 Jun;45(6):1735-45. Epub 2007 Apr 18.

8.
11.

[Vaginal candidiasis: etiology and sensitivity profile to antifungal agents in clinical use].

Saporiti AM, Gómez D, Levalle S, Galeano M, Davel G, Vivot W, Rodero L.

Rev Argent Microbiol. 2001 Oct-Dec;33(4):217-22. Spanish.

PMID:
11833253
13.

In vitro susceptibilities of yeast species to fluconazole and voriconazole as determined by the 2010 National China Hospital Invasive Fungal Surveillance Net (CHIF-NET) study.

Wang H, Xiao M, Chen SC, Kong F, Sun ZY, Liao K, Lu J, Shao HF, Yan Y, Fan H, Hu ZD, Chu YZ, Hu TS, Ni YX, Zou GL, Xu YC.

J Clin Microbiol. 2012 Dec;50(12):3952-9. doi: 10.1128/JCM.01130-12. Epub 2012 Oct 3.

14.

Antifungal susceptibility profiles of bloodstream yeast isolates by Sensititre YeastOne over nine years at a large Italian teaching hospital.

Posteraro B, Spanu T, Fiori B, De Maio F, De Carolis E, Giaquinto A, Prete V, De Angelis G, Torelli R, D'Inzeo T, Vella A, De Luca A, Tumbarello M, Ricciardi W, Sanguinetti M.

Antimicrob Agents Chemother. 2015 Jul;59(7):3944-55. doi: 10.1128/AAC.00285-15. Epub 2015 Apr 20.

15.

[Prerequisites for effective therapy of chronic recurrent vaginal candidiasis].

Kunzelmann V, Tietz HJ, Rossner D, Czaika V, Hopp M, Schmalreck A, Sterry W.

Mycoses. 1996;39 Suppl 1:65-72. German.

PMID:
8767274
16.

In vitro susceptibility of oral Candida to seven antifungal agents.

Kuriyama T, Williams DW, Bagg J, Coulter WA, Ready D, Lewis MA.

Oral Microbiol Immunol. 2005 Dec;20(6):349-53.

PMID:
16238594
17.

In vitro activity of nystatin compared with those of liposomal nystatin, amphotericin B, and fluconazole against clinical Candida isolates.

Arikan S, Ostrosky-Zeichner L, Lozano-Chiu M, Paetznick V, Gordon D, Wallace T, Rex JH.

J Clin Microbiol. 2002 Apr;40(4):1406-12.

18.

In vitro fluconazole and nystatin susceptibility and clinical outcome in complicated vulvovaginal candidosis.

Fan SR, Liu XP.

Mycoses. 2011 Nov;54(6):501-5. doi: 10.1111/j.1439-0507.2010.01887.x. Epub 2010 Apr 6.

PMID:
20406393
19.
20.

Supplemental Content

Support Center